EU and US could reach trade deal this weekend - Reuters
SAN FRANCISCO - FibroGen, Inc. (NASDAQ: FGEN) has announced the appointment of Dr. Michael Kauffman to its Board of Directors, effective last Monday. Dr. Kauffman, a seasoned figure in the biotechnology industry with approximately 30 years of experience, joins the company as it aims to advance its drug development pipeline, particularly in oncology. According to InvestingPro data, FibroGen faces significant financial challenges with a market capitalization of just $32 million and a concerning cash burn rate.
Dr. Kauffman’s career spans various senior roles in the life sciences sector, with a focus on oncology therapeutics. He currently holds positions as CEO and president of Nereid Therapeutics Inc., and serves on the boards of several other biotech companies including Verastem Oncology, FoRx Therapeutics, Kezar Life Sciences, Incendia Therapeutics, and BiVictriX Therapeutics. His appointment comes at a critical time as FibroGen’s stock has declined over 70% in the past year, with revenue dropping more than 80% in the last twelve months.
Previously, Dr. Kauffman co-founded Karyopharm Therapeutics and oversaw its growth from a discovery stage company to a commercial entity, leading to the global approval of its cancer drug XPOVIO®. His earlier work includes serving as CMO of Onyx Pharmaceuticals, where he led the development of Kyprolis® after the company’s acquisition of Proteolix Inc.
FibroGen’s Chairman, James Schoeneck, expressed confidence in Dr. Kauffman’s expertise, particularly in drug development and regulatory strategy, which is expected to be valuable as the company approaches significant clinical milestones. Dr. Kauffman also conveyed his enthusiasm for joining FibroGen during a pivotal period for the organization.
FibroGen is engaged in the development of novel therapies for cancer biology and anemia. Its product Roxadustat is approved in several countries for the treatment of anemia in chronic kidney disease patients, and the company is considering further development plans in the U.S. Additionally, FibroGen is working on FG-3246, an antibody-drug conjugate aimed at treating metastatic castration-resistant prostate cancer, along with an associated PET biomarker FG-3180. InvestingPro analysis reveals challenging financials with negative EBITDA of $94 million and analysts forecasting continued sales decline this year. For deeper insights into FibroGen’s financial health and growth prospects, including 10+ additional ProTips, access the comprehensive Pro Research Report available on InvestingPro.
The addition of Dr. Kauffman to the Board is part of FibroGen’s strategic efforts to strengthen its governance and leadership as it continues to pursue advancements in its therapeutic programs. With a current ratio of 2.02, the company maintains adequate short-term liquidity despite its challenges. This appointment is based on a press release statement from FibroGen, Inc.
In other recent news, FibroGen Inc. reported a significant decrease in revenue for the first quarter of 2025, with earnings dropping to $2.7 million from $25.4 million the previous year. Despite this decline, the company successfully reduced its net loss to $16.8 million, down from $49 million year-over-year. FibroGen is also in the process of divesting its Chinese operations to AstraZeneca, a transaction expected to close in the third quarter of 2025. This move is anticipated to enhance the company’s financial stability by providing an estimated $185 million, which will be used to pay down debt and extend its cash runway into the second half of 2027.
Additionally, FibroGen has promising developments in its drug pipeline, particularly in prostate cancer and anemia treatments. The company is planning a Phase II monotherapy trial for FG3246 in prostate cancer, with the trial expected to start in the third quarter. Analyst firms have not provided any upgrades or downgrades for FibroGen, but the company’s strategic initiatives and cost management have been positively received by the market. These recent developments reflect FibroGen’s efforts to navigate its current challenges and capitalize on future opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.